Novo Nordisk A/S (NYSE:NVO) Shares Sold by Calamos Wealth Management LLC

Calamos Wealth Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 37.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,413 shares of the company’s stock after selling 11,742 shares during the quarter. Calamos Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,670,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $48,000. Dunhill Financial LLC lifted its stake in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after purchasing an additional 311 shares during the last quarter. Finally, Albion Financial Group UT lifted its stake in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $82.64 on Tuesday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a market cap of $370.85 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The business has a 50 day moving average price of $93.56 and a two-hundred day moving average price of $112.87.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.